Literature DB >> 11934876

Lipocalin allergen Bos d 2 is a weak immunogen.

Soili Saarelainen1, Thomas Zeiler, Jaakko Rautiainen, Ale Närvänen, Marja Rytkönen-Nissinen, Rauno Mäntyjärvi, Pekka Vilja, Tuomas Virtanen.   

Abstract

The immunological characteristics of an important group of animal-derived allergens, lipocalins, are poorly known. To explore the immunology of the lipocalin allergen Bos d 2, several mouse strains with different H-2 haplotypes were immunized with the allergen. Only the BALB/c mouse mounted a distinct humoral response against Bos d 2. The proliferative spleen cell responses of all mouse strains remained very weak. Further experiments with BALB/c mice confirmed that Bos d 2 is a weak inducer of both humoral and cellular responses, and that the responses were weaker than with the control antigens hen egg lysozyme (HEL) and tetanus toxoid. IgG subclass analyses showed that Bos d 2 was prone to favor the T(h)2 response. Although s.c. immunization using complete Freund's adjuvant favored the T(h)1-deviated immune response by lymph node cells, Bos d 2 was able to induce the production of IL-4 while the control antigen HEL did not. Epitope mapping revealed that BALB/c mice recognized one immunodominant epitope in Bos d 2, almost identical to that recognized by humans. The epitope was shown to be immunogenic in subsequent experiments. However, further studies are needed to clarify the significance of priming and stimulation doses of the immunodominant and other epitopes in Bos d 2 for the outcome of immune response against the allergen. The murine immune response against Bos d 2 closely resembled that observed in humans. The weak immunogenicity of Bos d 2 may be associated with its allergenicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934876     DOI: 10.1093/intimm/14.4.401

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Reply to the letter to the editor concerning the review Immunotherapy for pet allergies.

Authors:  Tuomas Virtanen
Journal:  Hum Vaccin Immunother       Date:  2018-04-11       Impact factor: 3.452

2.  Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues.

Authors:  Soili A Saarelainen; Tuure T Kinnunen; Cécile Buhot; Ale T O Närvänen; Anu K Kauppinen; Marja A Rytkönen-Nissinen; Bernard Maillere; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

3.  Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome.

Authors:  Matthias Egger; Alexander Jürets; Michael Wallner; Peter Briza; Silke Ruzek; Stefan Hainzl; Ulrike Pichler; Claudia Kitzmüller; Barbara Bohle; Christian G Huber; Fátima Ferreira
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

Review 4.  Addressing Molecular Diagnosis of Occupational Allergies.

Authors:  Monika Raulf; Santiago Quirce; Olivier Vandenplas
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-14       Impact factor: 4.806

Review 5.  Inhalant Mammal-Derived Lipocalin Allergens and the Innate Immunity.

Authors:  Tuomas Virtanen
Journal:  Front Allergy       Date:  2022-01-27

6.  Human CD4+ T cell responses to the dog major allergen Can f 1 and its human homologue tear lipocalin resemble each other.

Authors:  Aino L K Liukko; Tuure T Kinnunen; Marja A Rytkönen-Nissinen; Anssi H T Kailaanmäki; Jukka T Randell; Bernard Maillère; Tuomas I Virtanen
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

7.  Commentary: Allergen and Epitope Targets of Mouse-Specific T Cell Responses in Allergy and Asthma.

Authors:  Tuomas Virtanen; Marja Rytkönen-Nissinen
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.